Short Interest in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) Rises By 428.3%

iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totaling 6,747 shares, a growth of 428.3% from the December 31st total of 1,277 shares. Based on an average daily trading volume, of 40,604 shares, the short-interest ratio is presently 0.2 days. Currently, 0.1% of the shares of the company are sold short. Currently, 0.1% of the shares of the company are sold short. Based on an average daily trading volume, of 40,604 shares, the short-interest ratio is presently 0.2 days.

iShares Genomics Immunology and Healthcare ETF Stock Performance

IDNA opened at $29.09 on Friday. The company has a fifty day moving average of $27.32 and a two-hundred day moving average of $24.73. The stock has a market capitalization of $145.45 million, a price-to-earnings ratio of 14.76 and a beta of 1.07. iShares Genomics Immunology and Healthcare ETF has a fifty-two week low of $17.26 and a fifty-two week high of $30.30.

Hedge Funds Weigh In On iShares Genomics Immunology and Healthcare ETF

A number of hedge funds have recently bought and sold shares of the business. Portland Global Advisors LLC grew its holdings in iShares Genomics Immunology and Healthcare ETF by 0.7% in the third quarter. Portland Global Advisors LLC now owns 103,007 shares of the company’s stock valued at $2,432,000 after purchasing an additional 684 shares during the period. Ameriprise Financial Inc. grew its stake in iShares Genomics Immunology and Healthcare ETF by 8.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 71,473 shares of the company’s stock valued at $1,688,000 after acquiring an additional 5,540 shares during the period. Flow Traders U.S. LLC purchased a new stake in iShares Genomics Immunology and Healthcare ETF in the 2nd quarter worth $931,000. Finally, Triumph Capital Management purchased a new stake in iShares Genomics Immunology and Healthcare ETF in the 3rd quarter worth $35,000.

About iShares Genomics Immunology and Healthcare ETF

The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.